Valeant stock is showing signs of heavy accumulation following a brutal drug pricing scandal and could reach the upper $30s in 2018.
Bill Ackman's Pershing Square exited its positions in Nomad Foods and Air Products & Chemicals.
Trading around gaps could show if the recovery party in Valeant stock is already over or just getting started.
Valeant won approval for its glaucoma drug, which sent the stock higher in pre-market action.
Bill Ackman's Pershing Square Capital will liquidate its $470 million-share in Nomad Foods.
Pershing Capital's 8.3% stake and actions to control ADP's board should attract speculative buying interest.
Reports that billionaire Bill Ackman might be accumulating a stake in Automatic Data Processing have caused shares of the company to rise quickly.
The multinational company saw its stock decline by nearly 2% at market open.
Valeant might be the biggest victim of the FDA’s bid to lower drug prices by boosting generic competition.
Bill Ackman may reap the benefits if Blackstone Group buys half of Platform Specialty Products.